RU2425838C2 - Ингибиторы iap - Google Patents

Ингибиторы iap Download PDF

Info

Publication number
RU2425838C2
RU2425838C2 RU2006139010/04A RU2006139010A RU2425838C2 RU 2425838 C2 RU2425838 C2 RU 2425838C2 RU 2006139010/04 A RU2006139010/04 A RU 2006139010/04A RU 2006139010 A RU2006139010 A RU 2006139010A RU 2425838 C2 RU2425838 C2 RU 2425838C2
Authority
RU
Russia
Prior art keywords
methylamino
pyrrolidinyl
propanamide
cyclohexyl
oxo
Prior art date
Application number
RU2006139010/04A
Other languages
English (en)
Other versions
RU2006139010A (ru
Inventor
Марк Г. ПАЛЕРМО (US)
Марк Г. Палермо
Сушил Кумар ШАРМА (US)
Сушил Кумар Шарма
Кристофер СТРОБ (US)
Кристофер СТРОБ
Руньмин ВАН (US)
Руньмин ВАН
Ли ЗАУЕЛ (US)
Ли ЗАУЕЛ
Яньлинь ЧЖАН (US)
Яньлинь ЧЖАН
Чжолян ЧЭНЬ (US)
Чжолян ЧЭНЬ
Япин ВАН (US)
Япин Ван
Фань ЯН (US)
Фань Ян
Войцех ВРОНА (US)
Войцех Врона
Ган ЛЮ (US)
Ган Лю
Марк Г. ЧАРЕСТ (US)
Марк Г. Чарест
Фэн ХЕ (US)
Фэн ХЕ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962601&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2425838(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2006139010A publication Critical patent/RU2006139010A/ru
Application granted granted Critical
Publication of RU2425838C2 publication Critical patent/RU2425838C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к новым соединениям формулы (IVa), которые ингибируют связывание белка Smac с ингибитором белков апоптоза (IAP).1н.и 3 з.п. ф-лы.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115

Claims (4)

1. Соединение формулы IVa
Figure 00000116

где R1 означает Н или С1-С4алкил;
R2 означает Н или С1-С4алкил;
R3 означает С1-С4алкил;
R4 означает циклогексил, циклопентил или С1-С4алкил;
R5 означает Н;
U означает группу формулы V
Figure 00000117

где n равно 0;
X означает N;
Rc означает Н;
Rd означает Ar1-D-Ar2, где D означает -СН2-, -CF2-, -O-, -С(O)-, -S-, -S(O)-, -S(O)2, 1,3-диоксолан или -N(Rh), где Rh означает Н, С1-С7алкил, -СF3, -СН2СН2ОН, -С(O)Н или -SO2СН3, и Ar1 и Аr2 означают замещенный или незамещенный арил или het, где указанный het, который может быть замещен метилом, выбран из пиридинила, пиримидинила, тетразолила, триазолила, пиразолила, оксазолила, тиазолила, 1,2,4-оксадиазолила, пирролила, имидазолила, пиразинила или триазинила, а указанный арил означает фенил, который может быть замещен одним или двумя галогенами;
R6, R7, R6' и R7' каждый означает Н;
или его фармацевтически приемлемая соль.
2. Соединение по п.1, где Ar1 означает пиридинил или тиазолил, а Аr3 означает фенил, который может быть замещен одним или двумя галогенами; или его фармацевтически приемлемая соль.
3. Соединение по п.1 или 2, где D означает -СН2-, -CF2-, -О- или -С(O)-, или его фармацевтически приемлемая соль.
4. Соединение по п.1, выбранное из группы, включающей:
Figure 00000118

N-[(1S)]-1-циклогексил-2-[(2S)-2[6-[(2-фторфенил)метиламино]-2-пиридинил]-1-пирролидинил]-2-оксоэтил]-2(метиламино)-(2S)-пропанамид;
Figure 00000119

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[2-(фенилметил)-2Н-тетразол-5-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-бутанамид;
Figure 00000120

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(3-феноксифенил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000121

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[5-(фенилметил)-1,2,4-оксадиазол-3-ил1]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000122

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[1-(фенилметил)-1Н-имидазол-4-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000123

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[6-(фенилметил)пиразинил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000124

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[4-(фенилметил)-1,3,5-триазин-2-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000125

N-[(1S)-1-циклогексил-2-[(2S)-2-[2-[(4-фторфенил)метиламино]-4-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000126

N-[(1S)-1-циклoгeкcил-2-oкco-2-[(2S)-2-[1-(фeнилмeтил)-1H-пиppoл-3-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000127

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[2-(фениламино)-5-оксазолил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000128

N-[(1S)-2-[(2S)-2-(5-бензоил-1,2,4-оксадиазол-3-ил)-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000129

N-[(1S)-2-[(2S)-2-(4-бензоил-2-тиазолил)-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000130

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[4-(2-фенил-1,3-диоксолан-2-ил)-2-оксазолил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000131

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[4-(фенилметил)-2-оксазолил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000132

N-[(1S)-2-[(2S)-2-(4-бензоил-5-метил-2-оксазолил)-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000133

N-[(1S)-2-[(2S)-2-(4-бензоил-2-оксазолил)-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000134

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[1-(фенилметил)-1Н-пиразол-4-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000135

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[1-(фенилметил)-1Н-1,2,3-триазол-4-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000136

N-[(1S)-1-циклогексил-2-[(2S)-2-[2-фтор-5-(метил-2-пиридиниламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000137

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-(метил-2-пиримидиниламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000138

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-(метил-2-пиридиниламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000139

N-[(1S)-1-циклогексил-2-[(2S)-2-[6-(метил-2-пиридиниламино)-2-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000140

N-[(1S)-1-циклогексил-2-[(2S)-2-[6-[(2,4-дифторфенил)метиламино]-2-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000141

N-[(1S)-2-[(2S)-2-[6-[(3-хлорфенил)метиламино]-2-пиридинил]-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000142

N-[(1S)-1-циклогексил-2-[(2S)-2-[6-[(4-фторфенил)метиламино]-2-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000143

N-[(1S)-1-циклогексил-2-[(2S)-2-[6-(метилфениламино)-2-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000144

N-[(1S)-1-циклогексил-2-[(2S)-2-[2-[(2-фторфенил)метиламино]-4-пиридинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000145

N-[(1S)-1-циклогексил-2-[(2S)-2-[2-[(2-фторфенил)метиламино]-4-пиримидинил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000146

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-[фенил(трифторметил)амино]фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000147

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-[(2-гидроксиэтил)фениламино]фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000148

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-(формилфениламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000149

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-[(метилсульфонил)фениламино]фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000150

N-[(1S)-1-циклопентил-2-[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000151

N-[(1S)-2,2-диметил-1-[[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]карбонил]пропил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000152

2-(метиламино)-N-[(1S)-3-метил-1-[[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]карбонил]бутил]-(2S)-пропанамид,
Figure 00000153

2-(метиламино)-N-[(1S)-1-[[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]карбонил]пропил]-(2S)-пропанамид;
Figure 00000154

2-(метиламино)-N-[(1S)-1-метил-2-[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]-2-оксоэтил]-(2S)-пропанамид;
Figure 00000155

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(фениламино)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000156

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(3-пиридинилокси)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000157

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(2-фенокси-4-пиримидинил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000158

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(2-фенокси-4-пиридинил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000159

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(5-фенокси-3-пиридинил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000160

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(6-фенокси-2-пиридинил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000161

N-[(1S)-2,2-диметил-1-[[(2S)-2-(3-феноксифенил)-1-пирролидинил]карбонил]пропил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000162

N-[(1S)-1-циклопентил-2-оксо-2-[(2S)-2-(3-феноксифенил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000163

2-(метиламино)-N-[(1S)-3-метил-1-[[(2S)-2-(3-феноксифенил)-1-пирролидинил]карбонил]бутил]-(2S)-пропанамид;
Figure 00000164

2-(метиламино)-N-[(1S)-1-[[(2S)-2-(3-феноксифенил)-1-пирролидинил]карбонил]пропил]-(2S)-пропанамид;
Figure 00000165

2-(метиламино)-N-[(1S)-1-метил-2-оксо-2-[(2S)-2-(3-феноксифенил)-1-пирролидинил]этил]-(2S)-пропанамид;
Figure 00000166

2-(метиламино)-N-[(1S)-2-метил-1-[[(2S)-2-(3-феноксифенил)-1-пирролидинил]карбонил]пропил]-(2S)-пропанамид;
Figure 00000167

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(2-феноксифенил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000168

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(4-феноксифенил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000169

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(2-фенил-1,3-диоксолан-2-ил)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000170

N-[(1S)-2-[(2S)-2-(3-бензоилфенил)-1-пирролидинил]-1-циклогексил-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000171

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-(дифторфенилметил)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000172

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(фенилсульфинил)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000173

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(фенилсульфонил)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000174

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[1-(фенилметил)-1Н-тетразол-5-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-бутанамид;
Figure 00000175

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[1-(фенилметил)-1Н-тетразол-5-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000176

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[2-(фенилметил)-2Н-тетразол-5-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-бутанамид;
Figure 00000177

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[2-(фенилметил)-2Н-тетразол-5-ил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000178

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(фенилтио)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000179

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-(3-феноксифенил)-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000180

N-[(1S)-1-циклогексил-2-[(2S)-2-[3-(метилфениламино)фенил]-1-пирролидинил]-2-оксоэтил]-2-(метиламино)-(2S)-пропанамид;
Figure 00000181

2-(мeтилaминo)-N-[(1S)-2-мeтил-1-[[(2S)-2-[3-(мeтилфeнилaминo)фeнил]-1-пирролидинил]карбонил]пропил]-(2S)-пропанамид; и
Figure 00000182

N-[(1S)-1-циклогексил-2-оксо-2-[(2S)-2-[3-(фенилметил)фенил]-1-пирролидинил]этил]-2-(метиламино)-(2S)-пропанамид;
или его фармацевтически приемлемая соль.
RU2006139010/04A 2004-04-07 2005-04-06 Ингибиторы iap RU2425838C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56018604P 2004-04-07 2004-04-07
US60/560,186 2004-04-07

Publications (2)

Publication Number Publication Date
RU2006139010A RU2006139010A (ru) 2008-05-20
RU2425838C2 true RU2425838C2 (ru) 2011-08-10

Family

ID=34962601

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006139010/04A RU2425838C2 (ru) 2004-04-07 2005-04-06 Ингибиторы iap

Country Status (32)

Country Link
US (4) US20080242658A1 (ru)
EP (3) EP2253614B1 (ru)
JP (3) JP4691549B2 (ru)
KR (2) KR20080083220A (ru)
CN (1) CN1964970B (ru)
AR (1) AR048927A1 (ru)
AU (1) AU2005231956B2 (ru)
BR (1) BRPI0509721A (ru)
CA (1) CA2560162C (ru)
CY (1) CY1113511T1 (ru)
DK (1) DK2253614T3 (ru)
EC (1) ECSP066893A (ru)
ES (2) ES2394441T3 (ru)
HK (1) HK1100930A1 (ru)
HR (1) HRP20121023T1 (ru)
IL (1) IL178104A (ru)
MA (1) MA28630B1 (ru)
ME (1) ME02125B (ru)
MY (1) MY165401A (ru)
NO (1) NO20065114L (ru)
NZ (1) NZ549925A (ru)
PE (2) PE20110102A1 (ru)
PL (1) PL2253614T3 (ru)
PT (1) PT2253614E (ru)
RS (1) RS52545B (ru)
RU (1) RU2425838C2 (ru)
SG (1) SG152225A1 (ru)
SI (1) SI2253614T1 (ru)
TN (1) TNSN06323A1 (ru)
TW (1) TWI417092B (ru)
WO (1) WO2005097791A1 (ru)
ZA (1) ZA200607696B (ru)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5122275B2 (ja) 2004-03-23 2013-01-16 ジェネンテック， インコーポレイテッド Ｉａｐのアザビシクロ−オクタンインヒビター
KR20080083220A (ko) * 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
WO2006014361A1 (en) 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
EP1773766B1 (en) 2004-07-15 2014-04-02 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ES2349110T5 (es) * 2004-12-20 2013-11-27 Genentech, Inc. Inhibidores de IAP derivados de pirrolidina
EP1879574A2 (en) * 2005-02-23 2008-01-23 Prexa Pharmaceuticals, Inc. Multimediator 5-ht6 receptor antagonists, and uses related thereto
US7517906B2 (en) 2005-02-25 2009-04-14 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
WO2006107964A2 (en) * 2005-04-06 2006-10-12 Novartis Ag Processes to prepare 6-phenethyl-octahydro-pyrrolo [2 , 3-c] pyridine and related compounds
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
KR20080067357A (ko) 2005-10-25 2008-07-18 에게라 쎄라퓨틱스 인코포레이티드 Ｉａｐ ｂｉｒ 도메인 결합 화합물
CN101374829A (zh) 2005-12-19 2009-02-25 健泰科生物技术公司 Iap的抑制剂
ES2684120T3 (es) 2005-12-20 2018-10-01 Novartis Ag Combinación de un inhibidor de IAP y un taxano
TWI543988B (zh) * 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
KR20080109068A (ko) * 2006-04-05 2008-12-16 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
MX2008012716A (es) * 2006-04-05 2008-10-14 Novartis Ag Combinaciones de agentes terapeuticos para el tratamiento de cancer.
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
ES2637592T3 (es) 2006-04-14 2017-10-13 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
MX2008014502A (es) * 2006-05-16 2008-11-27 Aegera Therapeutics Inc Compuestos de union a dominio de repeticion de proteinas inhibidoras de apoptosis baculovirales de las proteinas inhibidoras de apoptosis.
US8163792B2 (en) * 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
WO2008014240A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
KR20090041391A (ko) * 2006-07-24 2009-04-28 테트랄로직 파마슈티칼스 이량체성 ｉａｐ 길항제
JP5452223B2 (ja) 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
KR20090065548A (ko) * 2006-10-12 2009-06-22 노파르티스 아게 Ｉａｐ 억제제로서의 피롤리딘 유도체
US20100316573A1 (en) * 2006-10-19 2010-12-16 Larry Alexander Gaither Organic Compounds
PT2089024E (pt) * 2006-11-28 2011-08-31 Novartis Ag Combinação de inibidores de iap e inibidores de flt3
US20100076013A1 (en) * 2006-11-28 2010-03-25 Novartis Ag Methods of Treatment
KR20090094461A (ko) * 2006-12-19 2009-09-07 제넨테크, 인크. Ｉａｐ의 이미다조피리딘 억제제
WO2008109057A1 (en) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
MX2009010667A (es) 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
TWI432212B (zh) * 2007-04-30 2014-04-01 Genentech Inc Ｉａｐ抑制劑
CA2686638A1 (en) * 2007-05-07 2008-11-13 Tetralogic Pharmaceuticals Corp. Tnf.alpha. gene expression as a biomarker of sensitivity to antagonists of inhibitor of apoptosis proteins
US20100203012A1 (en) * 2007-05-30 2010-08-12 Aegera Therapeutics, Inc. Iap bir domain binding compounds
SI2240506T1 (sl) * 2008-01-11 2013-04-30 Genentech, Inc. Inhibitorji IAP
EP2242362A4 (en) * 2008-01-24 2012-04-11 Tetralogic Pharm Corp INHIBITORS OF APOPTOSIS PROTEINS
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
BRPI0912692A2 (pt) * 2008-05-16 2017-03-21 Dana Farber Cancer Inst Inc imunomodulação através de inibidores de iap
CA2728933A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
EP2318395A4 (en) 2008-08-02 2011-10-26 Genentech Inc IPA INHIBITORS
NZ590500A (en) * 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap
WO2010033531A1 (en) * 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US8841067B2 (en) 2009-01-09 2014-09-23 Dana-Farber Cancer Institute, Inc. NOL3 is a predictor of patient outcome
WO2010138496A1 (en) * 2009-05-28 2010-12-02 Tetralogic Pharmaceuticals Corp. Iap inhibitors
US8415486B2 (en) 2009-05-28 2013-04-09 Tetralogic Pharmaceuticals Corp. IAP inhibitors
CN101928326B (zh) * 2009-06-24 2015-07-08 中国人民解放军军事医学科学院毒物药物研究所 取代的氨酰基五元杂环烷类化合物及其用途
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
UY32826A (es) 2009-08-04 2011-02-28 Takeda Pharmaceutical Compuestos heterocíclicos
BR112012003118A2 (pt) 2009-08-12 2016-02-23 Novartis Ag formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose
JP2013505446A (ja) 2009-09-18 2013-02-14 ノバルティス アーゲー Ｉａｐ阻害剤化合物のためのバイオマーカー
US8551955B2 (en) 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
CA2800260C (en) * 2010-04-19 2013-07-09 Sri International Compositions and method for the treatment of multiple myeloma
WO2012052758A1 (en) 2010-10-22 2012-04-26 Astrazeneca Ab Response biomarkers for iap antagonists in human cancers
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
EP2760446A1 (en) 2011-09-30 2014-08-06 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
GB201121122D0 (en) 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes and elastomer compositions containing them
GB201121124D0 (en) 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes
GB201121133D0 (en) * 2011-12-08 2012-01-18 Dow Corning Hydrolysable silanes
GB201121128D0 (en) 2011-12-08 2012-01-18 Dow Corning Treatment of filler with silane
GB201121132D0 (en) * 2011-12-08 2012-01-18 Dow Corning Modifying polymeric materials by amines
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
KR20150011822A (ko) 2012-05-04 2015-02-02 노파르티스 아게 Iap 억제제 요법을 위한 바이오마커
KR20140011773A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 이중 저해 활성을 갖는 헤테로고리 유도체
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
NZ710929A (en) 2013-03-15 2018-02-23 Novartis Ag Antibody drug conjugates
US20140303090A1 (en) * 2013-04-08 2014-10-09 Tetralogic Pharmaceuticals Corporation Smac Mimetic Therapy
NZ714347A (en) 2013-06-25 2020-01-31 Walter & Eliza Hall Inst Medical Res Method of treating intracellular infection
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US9278978B2 (en) * 2013-08-23 2016-03-08 Boehringer Ingelheim International Gmbh 6-Alkynyl Pyridine
US9249151B2 (en) * 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
RS62301B1 (sr) 2013-12-20 2021-09-30 Astex Therapeutics Ltd Biciklična heterociklična jedinjenja i njihove upotrebe u terapiji
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP6768522B2 (ja) 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
CN106659790A (zh) 2014-08-12 2017-05-10 诺华股份有限公司 抗cdh6抗体药物缀合物
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
BR112017015497A2 (pt) 2015-01-20 2018-01-30 Arvinas, Inc. composto, e, composição
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN104592214A (zh) * 2015-02-13 2015-05-06 佛山市赛维斯医药科技有限公司 含葡萄糖酰胺吡啶和烷氧吡嗪结构的化合物及用途
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
EP3322986A4 (en) * 2015-07-13 2018-09-05 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN105566447B (zh) * 2016-01-20 2019-09-20 广东工业大学 一种凋亡抑制蛋白的类肽拮抗剂及其合成方法与应用
CN105585583B (zh) * 2016-01-20 2018-04-13 广东工业大学 一种非肽类凋亡抑制蛋白拮抗剂及其合成方法与应用
CN106188098B (zh) * 2016-07-06 2017-11-03 广东工业大学 一种杂化抗癌药物及其制备方法与应用
CN109715620B (zh) * 2016-08-29 2022-05-06 密歇根大学董事会 作为alk抑制剂的氨基嘧啶
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
EP3689868B1 (en) 2016-12-01 2023-09-27 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
CA3047784A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
BR112019012682A2 (pt) 2016-12-23 2019-12-17 Arvinas Operations Inc moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CN114685602A (zh) * 2017-11-13 2022-07-01 正大天晴药业集团股份有限公司 用作iap抑制剂的smac模拟物及其用途
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
US11028088B2 (en) 2018-03-10 2021-06-08 Yale University Modulators of BTK proteolysis and methods of use
CN112218859A (zh) 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JOP20210001A1 (ar) 2018-07-10 2021-01-05 Novartis Ag مشتقات 3-(5- هيدروكسي -1- أوكسو أيزو إندولين -2- يل) بيبريدين -2، 6- دايون واستخدامها لمعالجة أمراض مرتبطة ببروتين ذات أصبع الزنك من عائلة (ikaros 2 (ikzf2
WO2020023851A1 (en) 2018-07-26 2020-01-30 Yale University Bifunctional substitued pyrimidines as modulators of fak proteolyse
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
KR102642203B1 (ko) 2018-09-07 2024-03-04 아비나스 오퍼레이션스, 인코포레이티드 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CN113195541B (zh) 2018-12-21 2024-08-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528A (zh) 2019-02-15 2021-10-08 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
AU2021288224A1 (en) 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
WO2024054591A1 (en) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
JPS59141547A (ja) 1983-02-01 1984-08-14 Eisai Co Ltd 鎮痛作用を有する新規ペプタイドおよび製法
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (ru) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CA2224435C (en) 1995-07-06 2008-08-05 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
IL126351A0 (en) 1996-04-12 1999-05-09 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
JP2000512990A (ja) 1996-06-24 2000-10-03 ファイザー・インク 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE69724269T2 (de) 1996-09-06 2004-06-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
DK1367057T3 (da) 1996-11-18 2009-01-19 Biotechnolog Forschung Gmbh Epothiloner E og F
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
BR9912938B1 (pt) 1998-08-11 2011-06-28 derivados de isoquinolina, composição que os compreende, processo para preparação e uso dos mesmos.
EP1135470A2 (en) 1998-11-20 2001-09-26 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
MXPA02000823A (es) * 2000-05-23 2002-07-30 Vertex Pharma Inhibidores de caspasa y uso de los mismos.
US6608026B1 (en) * 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20020160975A1 (en) * 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
AU2003249920A1 (en) * 2002-07-02 2004-01-23 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
CA2543897A1 (en) * 2003-11-13 2005-06-02 Genentech, Inc. Compositions and methods for screening pro-apoptotic compounds
US20100093645A1 (en) 2004-01-16 2010-04-15 Shaomeng Wang SMAC Peptidomimetics and the Uses Thereof
JP4674231B2 (ja) * 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
KR20080083220A (ko) * 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
WO2006014361A1 (en) 2004-07-02 2006-02-09 Genentech, Inc. Inhibitors of iap
ES2349110T5 (es) 2004-12-20 2013-11-27 Genentech, Inc. Inhibidores de IAP derivados de pirrolidina
PE20110217A1 (es) 2006-08-02 2011-04-01 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WO 2004005248 (A1) NOVARTIS AG 2004-01-15. WO 0190070 (А2) VERTEX PHARMA 2001-11-29. ARNT С R; ET AL "Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ." JOURNAL OF BIOLOGICAL CHEMISTRY, 2002 Vol:277, Nr:46, Page(s): 44236-44243 KIPP R A; ET AL "Molecular targeting of inhibitor of apoptosis based on small molecule mimics of natural binding partners" BIOCHEMISTRY, 2002 Vol:41, Nr:23, Page(s):7344-7349. WU J-W; ET AL "Structural analysis of a functional DIAPI Fragment bond to grim and hid peptides" MOLECULAR CELL, 2001, Vol:8, Nr:1, Page(s): 95-104. DEAL M J; ET AL "Conformationally Constrained Tachykinin Analogues: Potent and Highly Selective Neurokinin NK-2-Rceptor Antagonists" JOURNAL OF MEDICINAL CHEMISTRY, 1992, Vol:35, Nr:22, Page(s): 4195-4204. *

Also Published As

Publication number Publication date
TNSN06323A1 (en) 2008-02-22
RU2006139010A (ru) 2008-05-20
JP2013049733A (ja) 2013-03-14
SI2253614T1 (sl) 2013-01-31
EP2253614A1 (en) 2010-11-24
IL178104A (en) 2015-08-31
RS52545B (en) 2013-04-30
IL178104A0 (en) 2006-12-31
CN1964970A (zh) 2007-05-16
KR20080083220A (ko) 2008-09-16
US7419975B2 (en) 2008-09-02
CY1113511T1 (el) 2016-06-22
KR100892185B1 (ko) 2009-04-07
TW200602029A (en) 2006-01-16
WO2005097791A1 (en) 2005-10-20
NO20065114L (no) 2007-01-08
EP1735307A1 (en) 2006-12-27
EP2065368A1 (en) 2009-06-03
MY165401A (en) 2018-03-21
US20080242658A1 (en) 2008-10-02
KR20060134200A (ko) 2006-12-27
BRPI0509721A (pt) 2007-09-25
CN1964970B (zh) 2011-08-03
CA2560162A1 (en) 2005-10-20
ES2394441T3 (es) 2013-01-31
NZ549925A (en) 2010-08-27
JP4691549B2 (ja) 2011-06-01
PT2253614E (pt) 2013-01-09
JP2007532504A (ja) 2007-11-15
SG152225A1 (en) 2009-05-29
US20120207769A1 (en) 2012-08-16
US8338440B2 (en) 2012-12-25
MA28630B1 (fr) 2007-06-01
DK2253614T3 (da) 2013-01-07
AU2005231956B2 (en) 2009-11-05
US20110281875A1 (en) 2011-11-17
ZA200607696B (en) 2008-03-26
PE20060166A1 (es) 2006-04-25
ES2396195T3 (es) 2013-02-19
PE20110102A1 (es) 2011-02-07
AU2005231956A1 (en) 2005-10-20
HK1100930A1 (en) 2007-10-05
TWI417092B (zh) 2013-12-01
US20050234042A1 (en) 2005-10-20
PL2253614T3 (pl) 2013-03-29
ECSP066893A (es) 2006-11-24
JP2010215635A (ja) 2010-09-30
HRP20121023T1 (hr) 2013-01-31
US8207183B2 (en) 2012-06-26
EP2253614B1 (en) 2012-09-19
ME02125B (me) 2013-04-30
AR048927A1 (es) 2006-06-14
CA2560162C (en) 2013-05-21
EP1735307B1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
RU2425838C2 (ru) Ингибиторы iap
AR104566A2 (es) Forma cristalina de la sal diclorhidrato de ((1s)-1-(((2s)-2-(5-(4-(2-((2s)-1-((2s)-2-((metoxicarbonil)amino)-3-metilbutanoil)-2-pirrolidinil)-1h-imidazol-5-il)-4-bifenilil)-1h-imidazol-2-il)-1-pirrolidinil)carbonil)-2-metilpropil)carbamato de metilo
RU2436776C2 (ru) ДИАРИЛАМИН-СОДЕРЖАЩИЕ СОЕДИНЕНИЯ, КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРОВ с-КIT
JP2017518961A5 (ru)
RU2019103873A (ru) Гетероциклические агонисты рецептора апелина (apj) и их применение
RU2485131C2 (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой и содержащие их противогрибковые средства
RU2010142937A (ru) НОВЫЕ ПРОИЗВОДНЫЕ ПИПЕРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СТЕАРОИЛ-КоА ДЕСАТУРАЗЫ
JP2005511543A5 (ru)
RU98118906A (ru) Амидные производные или их соли
EA201000300A1 (ru) Способ синтеза соединений, пригодных для лечения гепатита с
CO6660490A2 (es) Composiciones solidas
NZ594981A (en) Hepatitis c virus inhibitors
CL2009001310A1 (es) Compuesto intermediario (2-clorofenil)-[2-(2-hidroxi-2-piridin-4-ilvinil)piridin-3-il]metanona o una sal del mismo en lapreparacion del compuesto {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]piridin-3-il}-(2-cloofenil)metanona (div. sol. 2680-04).
JP2005504100A5 (ru)
AR017219A1 (es) Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
JP2004532209A5 (ru)
JP2005526081A5 (ja) 代謝型グルタメート受容体−５の二アリール置換テトラゾールモジュレータ
RU2009125019A (ru) Производные карбоновой кислоты
JPWO2022173032A5 (ru)
RU2008137612A (ru) Амидное производное или его соли
JP2006527708A5 (ru)
RU2000100935A (ru) Производные ароил-пиперазина, их получение и их использование в качестве антагонистов тахикинина
RU2014142328A (ru) Производные пиперидина в качестве агонистов gpr119
RU97118474A (ru) Новые гетероциклические соединения
RU2014119543A (ru) Новые производные пиразина